Evaluation of serum interleukin‐1 receptor antagonist levels in major depressive disorder: A case‐control study
Abstract Background and Aims Major depressive disorder (MDD) is characterized by the occurrence of one or more depressive episodes lasting a minimum of 2 weeks and is marked by a persistently low mood and a lack of enjoyment in daily activities. The diagnosis of MDD is not possible by a well‐establi...
Main Authors: | Zabun Nahar, Shahrin Tasnim Monisha, MMA Shalahuddin Qusar, Md. Rabiul Islam |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-04-01
|
Series: | Health Science Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/hsr2.1175 |
Similar Items
-
Higher serum interleukin‐12 levels are associated with the pathophysiology of major depressive disorder: A case‐control study results
by: Zabun Nahar, et al.
Published: (2023-01-01) -
Altered IL-3 and lipocalin-2 levels are associated with the pathophysiology of major depressive disorder: a case-control study
by: Mst. Sarmin Akter, et al.
Published: (2023-11-01) -
Serum levels of interleukin-33 and mesencephalic astrocyte derived neurotrophic factors in patients with major depressive disorder: a cross-sectional comparative design
by: Zabun Nahar, et al.
Published: (2024-01-01) -
Interleukin-17 as a potential therapeutic target for chronic pain
by: Xiaojuan Jiang, et al.
Published: (2022-09-01) -
Interleukin-1 receptor antagonist: a promising cytokine against human squamous cell carcinomas
by: Yujie Ding, et al.
Published: (2023-04-01)